Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures

J. S. Gill, K. L. Hobday, Anthony John Windebank

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Suramin is an experimental chemotherapeutic agent which produces a severe dose-related neuropathy. Suramin inhibits axonal growth from rat dorsal root ganglion neurons. This inhibition is dose dependent and reversed by increasing nerve growth factor concentrations. In this study, myelinating dorsal root ganglion cultures were exposed to various concentrations of suramin and nerve growth factor. Effects were assessed with quantitative light and electron microscopy. Using a systematic sampling technique, suramin was observed to produce dose and time-dependent myelinated fiber degeneration. With 9-day exposure, there was no effect with suramin concentrations of 100 μM or less. At 200 μM, 17% of the myelinated fibers were degenerating at 4 days and 53.3% by 9 days. At 300 μM, this increased to 24 and 84%, respectively. At 671 μM, 72.7% of the myelinated fibers and at 1316 μM, 88.7% of the myelinated fibers were degenerating at 4 days. It appeared that secondary demyelination was the major process. Large multilamellar inclusion bodies filled Schwann cells, particularly those investing unmyelinated fibers and dorsal root ganglia neuron cell bodies. The size and frequency of these inclusions increased with prolonged exposure to suramin (300 μM). Immunohistochemistry revealed that the inclusions were composed primarily of GM1 ganglioside. These effects were not influenced by increasing nerve growth factor up to 500 ng/ml. We conclude that suramin causes injury to both axons and Schwann cells that is not prevented by NGF and produces an experimental form of GM1 gangliosidosis.

Original languageEnglish (US)
Pages (from-to)113-124
Number of pages12
JournalExperimental Neurology
Volume133
Issue number2
DOIs
StatePublished - 1995

Fingerprint

Suramin
Spinal Ganglia
Nerve Growth Factor
Schwann Cells
GM1 Gangliosidosis
G(M1) Ganglioside
Neurons
Inclusion Bodies
Demyelinating Diseases
Axons
Electron Microscopy
Immunohistochemistry
Light
Wounds and Injuries
Growth

ASJC Scopus subject areas

  • Neuroscience(all)
  • Developmental Neuroscience
  • Neurology

Cite this

Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures. / Gill, J. S.; Hobday, K. L.; Windebank, Anthony John.

In: Experimental Neurology, Vol. 133, No. 2, 1995, p. 113-124.

Research output: Contribution to journalArticle

@article{ca128e8b38f64bfa96536ccfc79c2aec,
title = "Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures",
abstract = "Suramin is an experimental chemotherapeutic agent which produces a severe dose-related neuropathy. Suramin inhibits axonal growth from rat dorsal root ganglion neurons. This inhibition is dose dependent and reversed by increasing nerve growth factor concentrations. In this study, myelinating dorsal root ganglion cultures were exposed to various concentrations of suramin and nerve growth factor. Effects were assessed with quantitative light and electron microscopy. Using a systematic sampling technique, suramin was observed to produce dose and time-dependent myelinated fiber degeneration. With 9-day exposure, there was no effect with suramin concentrations of 100 μM or less. At 200 μM, 17{\%} of the myelinated fibers were degenerating at 4 days and 53.3{\%} by 9 days. At 300 μM, this increased to 24 and 84{\%}, respectively. At 671 μM, 72.7{\%} of the myelinated fibers and at 1316 μM, 88.7{\%} of the myelinated fibers were degenerating at 4 days. It appeared that secondary demyelination was the major process. Large multilamellar inclusion bodies filled Schwann cells, particularly those investing unmyelinated fibers and dorsal root ganglia neuron cell bodies. The size and frequency of these inclusions increased with prolonged exposure to suramin (300 μM). Immunohistochemistry revealed that the inclusions were composed primarily of GM1 ganglioside. These effects were not influenced by increasing nerve growth factor up to 500 ng/ml. We conclude that suramin causes injury to both axons and Schwann cells that is not prevented by NGF and produces an experimental form of GM1 gangliosidosis.",
author = "Gill, {J. S.} and Hobday, {K. L.} and Windebank, {Anthony John}",
year = "1995",
doi = "10.1006/exnr.1995.1014",
language = "English (US)",
volume = "133",
pages = "113--124",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures

AU - Gill, J. S.

AU - Hobday, K. L.

AU - Windebank, Anthony John

PY - 1995

Y1 - 1995

N2 - Suramin is an experimental chemotherapeutic agent which produces a severe dose-related neuropathy. Suramin inhibits axonal growth from rat dorsal root ganglion neurons. This inhibition is dose dependent and reversed by increasing nerve growth factor concentrations. In this study, myelinating dorsal root ganglion cultures were exposed to various concentrations of suramin and nerve growth factor. Effects were assessed with quantitative light and electron microscopy. Using a systematic sampling technique, suramin was observed to produce dose and time-dependent myelinated fiber degeneration. With 9-day exposure, there was no effect with suramin concentrations of 100 μM or less. At 200 μM, 17% of the myelinated fibers were degenerating at 4 days and 53.3% by 9 days. At 300 μM, this increased to 24 and 84%, respectively. At 671 μM, 72.7% of the myelinated fibers and at 1316 μM, 88.7% of the myelinated fibers were degenerating at 4 days. It appeared that secondary demyelination was the major process. Large multilamellar inclusion bodies filled Schwann cells, particularly those investing unmyelinated fibers and dorsal root ganglia neuron cell bodies. The size and frequency of these inclusions increased with prolonged exposure to suramin (300 μM). Immunohistochemistry revealed that the inclusions were composed primarily of GM1 ganglioside. These effects were not influenced by increasing nerve growth factor up to 500 ng/ml. We conclude that suramin causes injury to both axons and Schwann cells that is not prevented by NGF and produces an experimental form of GM1 gangliosidosis.

AB - Suramin is an experimental chemotherapeutic agent which produces a severe dose-related neuropathy. Suramin inhibits axonal growth from rat dorsal root ganglion neurons. This inhibition is dose dependent and reversed by increasing nerve growth factor concentrations. In this study, myelinating dorsal root ganglion cultures were exposed to various concentrations of suramin and nerve growth factor. Effects were assessed with quantitative light and electron microscopy. Using a systematic sampling technique, suramin was observed to produce dose and time-dependent myelinated fiber degeneration. With 9-day exposure, there was no effect with suramin concentrations of 100 μM or less. At 200 μM, 17% of the myelinated fibers were degenerating at 4 days and 53.3% by 9 days. At 300 μM, this increased to 24 and 84%, respectively. At 671 μM, 72.7% of the myelinated fibers and at 1316 μM, 88.7% of the myelinated fibers were degenerating at 4 days. It appeared that secondary demyelination was the major process. Large multilamellar inclusion bodies filled Schwann cells, particularly those investing unmyelinated fibers and dorsal root ganglia neuron cell bodies. The size and frequency of these inclusions increased with prolonged exposure to suramin (300 μM). Immunohistochemistry revealed that the inclusions were composed primarily of GM1 ganglioside. These effects were not influenced by increasing nerve growth factor up to 500 ng/ml. We conclude that suramin causes injury to both axons and Schwann cells that is not prevented by NGF and produces an experimental form of GM1 gangliosidosis.

UR - http://www.scopus.com/inward/record.url?scp=0029144963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029144963&partnerID=8YFLogxK

U2 - 10.1006/exnr.1995.1014

DO - 10.1006/exnr.1995.1014

M3 - Article

C2 - 7649218

AN - SCOPUS:0029144963

VL - 133

SP - 113

EP - 124

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -